FDA slaps hold on Finch's C. diff med to get info on COVID-19 screening for donor-derived therapy

Finch Therapeutics' phase 3 trial for a Clostridioides difficile med has been placed on clinical hold by the FDA as the agency requests more information on how the biotech screens the donor-derived microbiome therapy for the virus that causes COVID-19.